MX2020012868A - Metodos y composiciones para trastornos del sue?o y otros trastornos. - Google Patents

Metodos y composiciones para trastornos del sue?o y otros trastornos.

Info

Publication number
MX2020012868A
MX2020012868A MX2020012868A MX2020012868A MX2020012868A MX 2020012868 A MX2020012868 A MX 2020012868A MX 2020012868 A MX2020012868 A MX 2020012868A MX 2020012868 A MX2020012868 A MX 2020012868A MX 2020012868 A MX2020012868 A MX 2020012868A
Authority
MX
Mexico
Prior art keywords
disorders
compositions
methods
sleep
treatment
Prior art date
Application number
MX2020012868A
Other languages
English (en)
Inventor
Sharon Mates
Allen A Fienberg
Lawrence P Wennogle
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41377435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020012868(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2020012868A publication Critical patent/MX2020012868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Abstract

Se describen compuestos de gamma-carbolina fusionados, heterocíclicos sustituidos, particulares como farmacéutico y composiciones farmacéuticas que los comprenden para el tratamiento de uno o más trastornos que involucran las trayectorias 5-HT2A, SERT y/o dopamina D2. Además, los compuestos pueden ser combinados con otros agentes terapéuticos para el tratamiento de uno o más trastornos del sueño, depresión, psicosis, discinesias y/o enfermedad de Parkinson o cualesquiera combinaciones.
MX2020012868A 2008-05-27 2010-11-26 Metodos y composiciones para trastornos del sue?o y otros trastornos. MX2020012868A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5643308P 2008-05-27 2008-05-27
US15503209P 2009-02-24 2009-02-24

Publications (1)

Publication Number Publication Date
MX2020012868A true MX2020012868A (es) 2022-06-14

Family

ID=41377435

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010013020A MX2010013020A (es) 2008-05-27 2009-05-27 Metodos y composiciones para trastornos del sueño y otros trastornos.
MX2020012868A MX2020012868A (es) 2008-05-27 2010-11-26 Metodos y composiciones para trastornos del sue?o y otros trastornos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010013020A MX2010013020A (es) 2008-05-27 2009-05-27 Metodos y composiciones para trastornos del sueño y otros trastornos.

Country Status (10)

Country Link
US (9) USRE48839E1 (es)
EP (2) EP2320731A4 (es)
JP (2) JP6106361B2 (es)
KR (4) KR102133073B1 (es)
CN (2) CN105168219B (es)
AU (1) AU2009251816B2 (es)
CA (1) CA2725342C (es)
HK (1) HK1219306A1 (es)
MX (2) MX2010013020A (es)
WO (1) WO2009145900A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105614A1 (en) 2006-10-25 2010-04-29 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (en) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
CA2679754C (en) 2007-03-12 2018-08-07 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
DK2262505T3 (en) 2008-03-12 2015-01-05 Intra Cellular Therapies Inc Substituted heterocyclic-CONCENTRATED GAMMA -carboline-SOLID
EP2320731A4 (en) 2008-05-27 2012-09-26 Intra Cellular Therapies Inc METHOD AND COMPOSITIONS FOR SLEEPING AND OTHER DISORDERS
EP2491038B1 (en) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
BR112012026881A2 (pt) * 2010-04-22 2017-10-10 Intra Cellular Therapies Inc compostos orgânicos
US8741888B2 (en) * 2010-11-09 2014-06-03 Carl A. Forest Sleep aid composition and method
HUE037649T2 (hu) * 2011-07-08 2018-09-28 Lilly Co Eli (Tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-il vegyületek, mint duális aktivitású H1 inverz agonisták/5-HT2A antagonisták
JP2015514135A (ja) * 2012-04-14 2015-05-18 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
CN103175973B (zh) * 2013-02-26 2015-05-13 首都医科大学 甘丙肽在制备女性抑郁症检测工具中的应用
US11235020B2 (en) * 2013-03-13 2022-02-01 Abraham Palmer Methods and compositions for inhibiting glyoxalase 1 (GLO1)
WO2014152804A1 (en) * 2013-03-14 2014-09-25 Hyperion Biotechnology Methods and compositions for biomarkers of fatigue, fitness and physical performance capacity
EP2968320B1 (en) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organic compounds
KR102372145B1 (ko) * 2013-12-03 2022-03-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
RU2016143091A (ru) 2014-04-04 2018-05-08 Интра-Селлулар Терапиз, Инк. Органические соединения
SI3125893T1 (sl) * 2014-04-04 2023-12-29 Intra-Cellular Therapies, Inc. Devterirani heterociklični zliti gama-karbolini kot antagonisti receptorjev 5-HT2A
KR20220071297A (ko) * 2015-01-28 2022-05-31 주식회사 제네리스코리아 신경정신계 장애의 치료를 위한 조성물 및 방법
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
CN108883111B (zh) 2016-01-26 2021-10-08 细胞内治疗公司 有机化合物
SI3426251T1 (sl) 2016-03-10 2022-07-29 Janssen Pharmaceutica Nv Postopki za zdravljenje depresije z antagonisti receptorja oreksina-2
CA3016353C (en) 2016-03-25 2021-04-27 Intra-Cellular Therapies, Inc. Deuterated fused heterocycle gamma-carbolines and compositions thereof useful in the treatment of nervous system disorders
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
EP3436083A4 (en) * 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
EP3436455A4 (en) * 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
EP3525763A4 (en) 2016-10-12 2020-06-17 Intra-Cellular Therapies, Inc. AMORPHE FIXED DISPERSIONS
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
KR20220066988A (ko) 2017-03-24 2022-05-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 조성물 및 방법
US11292793B2 (en) 2017-04-10 2022-04-05 Dr. Reddy's Laboratories Limited Solid dispersions of amorphous Lumateperone p-Tosylate
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
CN111093665A (zh) 2017-07-26 2020-05-01 细胞内治疗公司 有机化合物
CN111093664B (zh) * 2017-07-26 2023-06-02 细胞内治疗公司 有机化合物
WO2019067591A1 (en) * 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
KR102036909B1 (ko) * 2017-11-28 2019-10-25 한국과학기술원 신규 디스토니아 치료용 약학적 조성물
MX2020009668A (es) * 2018-03-16 2021-01-08 Intra Cellular Therapies Inc Métodos novedosos.
JP7462568B2 (ja) 2018-03-23 2024-04-05 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN110831941A (zh) 2018-06-11 2020-02-21 细胞内治疗公司 取代的杂环稠合的γ-咔啉类化合物合成
US11806311B2 (en) 2018-06-21 2023-11-07 Aquestive Therapeutics, Inc. System and method for making personalized individual unit doses containing pharmaceutical actives
JP2022500362A (ja) * 2018-08-29 2022-01-04 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規組成物および方法
AU2019331490A1 (en) 2018-08-31 2021-03-18 Intra-Cellular Therapies, Inc. Novel methods
BR112021004053A2 (pt) 2018-09-07 2021-05-25 Aquestive Therapeutics, Inc. composições de filme oral e formas de dosagem tendo perfis de dissolução de ativo precisos
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
KR102227268B1 (ko) * 2019-10-07 2021-03-12 한국과학기술원 디스토니아 치료 후보 약물의 신규 스크리닝 방법
CA3159382A1 (en) 2019-11-01 2021-05-06 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
KR20220126287A (ko) 2019-11-14 2022-09-15 어퀘스티브 테라퓨틱스, 아이엔씨. 멀티모달 조성물 및 치료 방법
WO2021119334A1 (en) * 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
IL301847A (en) * 2020-10-09 2023-06-01 Shujing Biopharma Co Ltd A modified heterocyclic γ-carboline derivative, a method of preparation thereof, its intermediate form and its use
KR20230134136A (ko) 2021-01-15 2023-09-20 어퀘스티브 테라퓨틱스, 아이엔씨. 전구약물 조성물 및 치료 방법
EP4304554A1 (en) 2021-03-09 2024-01-17 Aquestive Therapeutics, Inc. Dosage forms having equivalent biocomparable profiles
WO2023097316A1 (en) * 2021-11-29 2023-06-01 Editas Medicine, Inc. Engineered crispr/cas12a effector proteins, and uses thereof
US20230372336A1 (en) 2022-05-18 2023-11-23 Intra-Cellular Therapies, Inc. Novel methods
CN115067220B (zh) * 2022-06-16 2023-04-25 中国人民解放军军事科学院军事医学研究院 一种双通道小动物恐惧共情行为检测系统

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6552017B1 (en) * 1999-06-15 2003-04-22 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
WO2006081251A2 (en) 2005-01-25 2006-08-03 Celgene Corporation Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
WO2007025103A2 (en) 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Organic compounds for treating reduced dopamine receptor signalling activity
US7645752B2 (en) 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
CA2679754C (en) * 2007-03-12 2018-08-07 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
KR20100054812A (ko) 2007-08-01 2010-05-25 메디베이션 뉴롤로지 인코퍼레이티드 항정신병제 조합 치료제를 사용하여 정신분열증을 치료하기 위한 방법 및 조성물
US8475793B2 (en) * 2008-02-07 2013-07-02 Merck Sharp & Dohme Corp. Engineered anti-TSLPR antibodies
DK2262505T3 (en) * 2008-03-12 2015-01-05 Intra Cellular Therapies Inc Substituted heterocyclic-CONCENTRATED GAMMA -carboline-SOLID
EP2320731A4 (en) * 2008-05-27 2012-09-26 Intra Cellular Therapies Inc METHOD AND COMPOSITIONS FOR SLEEPING AND OTHER DISORDERS
BR112012026881A2 (pt) 2010-04-22 2017-10-10 Intra Cellular Therapies Inc compostos orgânicos
JP2015514135A (ja) 2012-04-14 2015-05-18 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
EP2968320B1 (en) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organic compounds
KR102372145B1 (ko) * 2013-12-03 2022-03-07 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
SI3125893T1 (sl) * 2014-04-04 2023-12-29 Intra-Cellular Therapies, Inc. Devterirani heterociklični zliti gama-karbolini kot antagonisti receptorjev 5-HT2A
RU2016143091A (ru) * 2014-04-04 2018-05-08 Интра-Селлулар Терапиз, Инк. Органические соединения
CN108883111B (zh) * 2016-01-26 2021-10-08 细胞内治疗公司 有机化合物
US11014925B2 (en) * 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
EP3436455A4 (en) * 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
CN111093664B (zh) * 2017-07-26 2023-06-02 细胞内治疗公司 有机化合物

Also Published As

Publication number Publication date
KR20200134341A (ko) 2020-12-01
USRE48839E1 (en) 2021-12-07
CA2725342C (en) 2024-02-20
CA2725342A1 (en) 2009-12-03
US10117867B2 (en) 2018-11-06
EP3085231A1 (en) 2016-10-26
JP2011523949A (ja) 2011-08-25
EP2320731A4 (en) 2012-09-26
JP2015157828A (ja) 2015-09-03
KR102133073B1 (ko) 2020-07-10
US20110071080A1 (en) 2011-03-24
KR102184038B1 (ko) 2020-11-27
US9168258B2 (en) 2015-10-27
US9616061B2 (en) 2017-04-11
US20160030425A1 (en) 2016-02-04
KR20110022631A (ko) 2011-03-07
MX2010013020A (es) 2011-03-21
CN105168219A (zh) 2015-12-23
AU2009251816A1 (en) 2009-12-03
US20190183888A1 (en) 2019-06-20
KR102317698B1 (ko) 2021-10-25
US8598119B2 (en) 2013-12-03
WO2009145900A1 (en) 2009-12-03
US20170189398A1 (en) 2017-07-06
AU2009251816B2 (en) 2015-12-10
CN102105059B (zh) 2015-09-30
US20240041871A1 (en) 2024-02-08
KR20160135371A (ko) 2016-11-25
US20140050783A1 (en) 2014-02-20
CN105168219B (zh) 2018-11-20
US20230355616A1 (en) 2023-11-09
JP6106361B2 (ja) 2017-03-29
US20200405713A1 (en) 2020-12-31
EP2320731A1 (en) 2011-05-18
CN102105059A (zh) 2011-06-22
HK1219306A1 (zh) 2017-03-31
US10702522B2 (en) 2020-07-07
KR20190006606A (ko) 2019-01-18

Similar Documents

Publication Publication Date Title
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
BR112012018386A8 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
IN2012DN02177A (es)
IN2012DN02702A (es)
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
IN2012DN00754A (es)
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
CL2012001605A1 (es) Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño.
TW200716628A (en) Novel compounds
ZA201100034B (en) Pharmaceutical compositions for treatment of parkinson's disease
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MY156332A (en) Quinuclidine carbonate derivatives and medicinal composition thereof
IL201189A (en) Fluorization derivatifrone derivatives used as iron pellets in the treatment of neurodegenerative diseases, their preparation and their pharmaceutical preparations
EP2401263A4 (en) SUBSTITUTED AZOL DERIVATIVES, PHARMACEUTICAL COMPOSITION WITH THE DERIVATIVES AND METHOD FOR THE TREATMENT OF MORBUS PARKINSON THEREWITH
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists